The FDA approved on June 21 the prescribing of levetiracetam (Keppra, UCB Pharma) as an add-on treatment for partial-onset seizures in children 4 years or older who have epilepsy. The approval follows a randomized, double-blind, placebo-controlled trial conducted at 60 sites and involving 198 children aged 4 to 16 years
展开▼
